Abeona Therapeutics (NASDAQ:ABEO) Director Sells $103,693.60 in Stock

Posted by Francis Steltz on Jun 18th, 2026

Abeona Therapeutics Inc. (NASDAQ:ABEO – Get Free Report) Director Christine Berni Silverstein sold 18,160 shares of the company’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $5.71, for a total transaction of $103,693.60. Following the transaction, the director owned 119,562 shares of the company’s stock, valued at approximately $682,699.02. This represents a 13.19% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Abeona Therapeutics Price Performance

Abeona Therapeutics stock opened at $5.65 on Thursday. The company has a market cap of $321.99 million, a price-to-earnings ratio of 5.82 and a beta of 1.35. The firm’s fifty day moving average is $5.49 and its 200 day moving average is $5.19. The company has a quick ratio of 5.70, a current ratio of 5.89 and a debt-to-equity ratio of 0.03. Abeona Therapeutics Inc. has a 52-week low of $4.00 and a 52-week high of $7.54.

Abeona Therapeutics (NASDAQ:ABEO – Get Free Report) last released its quarterly earnings results on Wednesday, May 13th. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.03. The business had revenue of $8.72 million for the quarter, compared to analysts’ expectations of $4.57 million. Sell-side analysts forecast that Abeona Therapeutics Inc. will post -0.79 EPS for the current fiscal year.

Analyst Ratings Changes

ABEO has been the topic of several recent analyst reports. Oppenheimer reissued an “outperform” rating on shares of Abeona Therapeutics in a research note on Monday, March 9th. Stifel Nicolaus set a $17.00 target price on shares of Abeona Therapeutics in a research note on Tuesday, March 17th. HC Wainwright reissued a “buy” rating and issued a $20.00 target price on shares of Abeona Therapeutics in a research note on Thursday, May 28th. Finally, Wall Street Zen raised shares of Abeona Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Monday, June 1st. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $19.00.

View Our Latest Research Report on ABEO

Institutional Investors Weigh In On Abeona Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Royal Bank of Canada raised its stake in shares of Abeona Therapeutics by 49.6% in the first quarter. Royal Bank of Canada now owns 6,500 shares of the biopharmaceutical company’s stock valued at $29,000 after acquiring an additional 2,155 shares during the period. Rangeley Capital LLC increased its stake in Abeona Therapeutics by 4.2% in the 1st quarter. Rangeley Capital LLC now owns 60,000 shares of the biopharmaceutical company’s stock worth $269,000 after buying an additional 2,400 shares during the period. Renaissance Technologies LLC increased its stake in Abeona Therapeutics by 38.6% in the 1st quarter. Renaissance Technologies LLC now owns 161,082 shares of the biopharmaceutical company’s stock worth $722,000 after buying an additional 44,882 shares during the period. Sei Investments Co. increased its stake in Abeona Therapeutics by 142.4% in the 1st quarter. Sei Investments Co. now owns 172,460 shares of the biopharmaceutical company’s stock worth $773,000 after buying an additional 101,307 shares during the period. Finally, Dimensional Fund Advisors LP purchased a new position in Abeona Therapeutics in the 1st quarter worth about $154,000. Hedge funds and other institutional investors own 80.56% of the company’s stock.

Abeona Therapeutics Company Profile

(Get Free Report)

Abeona Therapeutics is a clinical‐stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life‐threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non‐viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company’s research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need.

The company’s lead clinical programs include separate AAV‐based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa.